Future Journal of Pharmaceutical Sciences最新文献

{"title":"Repurposing dapagliflozin for Alzheimer's disease: a mechanistic exploration","authors":"Marwa M. Saeed","doi":"10.1186/s43094-024-00751-w","DOIUrl":"10.1186/s43094-024-00751-w","url":null,"abstract":"<div><h3>Background</h3><p>Several researches describe Alzheimer’s disease (AD) as Type-III diabetes mellitus due to shared pathophysiological mechanisms between AD and DM and the fact that one disease can increase the incidence of the other. Therefore, keeping glucose level under control protects the brain from its harmful effects and delays the incidence of AD in susceptible individuals by using anti-diabetic agents. Several anti-diabetic classes were explored for their protective effect against AD, among them that attracted more attention was sodium–glucose cotransporter inhibitor dapagliflozin (DAPA).</p><h3>Main body of the abstract</h3><p>This review aims at illustrating various protective mechanisms that DAPA proved to exert on cognition and memory. DAPA showed promising results by its influence on behavioral parameters highlighted enhancement of both spatial and non-spatial learning and memory, in addition to ameliorating associated anxiety by its effect on various neurotransmitters. DAPA succeeded in promoting neurogenesis, synaptic plasticity, and synaptic density, and managed to demonstrate anti-inflammatory, antioxidant, and antiapoptotic properties. Moreover, DAPA enhanced the activity of mitochondria and promoted autophagy, in addition to its impact on the PI3K/AKT/mTOR and Wnt/β-catenin signaling pathways.</p><h3>Short conclusion</h3><p>DAPA showed promising results in different AD models to enhance memory and improve cognitive deficits.</p><h3>Graphical abstract</h3><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"10 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://fjps.springeropen.com/counter/pdf/10.1186/s43094-024-00751-w","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142844790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bioactive phytochemicals from leaf extract of Erlangea tomentosa S. Moore (Bothriocline longipes (Oliv. & Hiern.) used to treat bacterial infections in Uganda","authors":"Jane Namukobe,&nbsp;Yeremiah Ekyibetenga,&nbsp;Adebola Omowunmi Oyedeji,&nbsp;Robert Byamukama,&nbsp;Mathias Heydenrech","doi":"10.1186/s43094-024-00749-4","DOIUrl":"10.1186/s43094-024-00749-4","url":null,"abstract":"<div><h3>Background</h3><p>The leaves of <i>Erlangea tomentosa</i> (ET) are used to treat several bacterial infections like respiratory tract infections, skin infections, diarrhea and gastrointestinal disorders. However, there is limited information about the compounds responsible for its bacterial activities. The study aimed at isolation and characterisation of phytochemicals from the leaf extracts of ET.</p><h3>Results</h3><p>Three compounds were isolated from leaf extracts of ET and characterised. Two compounds; eriodictyol-7-<i>O</i>-β-glucoside (1) and 5, 7, 3′, 4′-tetrahydroxy-7-<i>O</i>-[6\"-<i>O</i>-(acetyl)-β-D-glucopyrancsyloxy]-flavanone (coccinoside A) (2) were identified from ethyl acetate extract while one compound; di-(2-ethylhexyl) phthalate (3) was identified from dichloromethane extract.</p><h3>Conclusion</h3><p>Compounds; 1, 2 and 3 were isolated and identified from ET and genus Erlangea for the first time. The reported antibacterial properties of compound 3 in literature could be responsible for the antibacterial activities of ET and the traditional use of ET.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"10 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://fjps.springeropen.com/counter/pdf/10.1186/s43094-024-00749-4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142798331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Spectrophotometric and HPLC analysis of amoxicillin trihydrate in presence of acetaminophen in different pH media","authors":"Aditi Bala,&nbsp;Sanchita Mandal","doi":"10.1186/s43094-024-00747-6","DOIUrl":"10.1186/s43094-024-00747-6","url":null,"abstract":"<div><h3>Background</h3><p>This study is aimed to develop a simple, effective and economic method for the UV spectrophotometric analysis of amoxicillin trihydrate in the presence of acetaminophen. The Beer–Lambert law was obeyed in the concentration range of 2–10 µg/ml for amoxicillin trihydrate, acetaminophen and combinations, in all the different pH media: pH 1.2, 6.8, 7.4 and neutral (double-distilled water). For the simultaneous equation method, the absorbance maxima of amoxicillin trihydrate was found at 228 nm, and for acetaminophen, it was found at 243 nm, after scanning the solutions in respective buffers.</p><h3>Result</h3><p>The standard curve of amoxicillin trihydrate and acetaminophen was plotted, and the correlation coefficient (R²) value was found to be in the range of 0.991–0.994 and 0.993–0.999, respectively. These two drugs were combined in a ratio of 5:3 (amoxicillin trihydrate: acetaminophen), and its absorbance maxima was discovered at 232 nm (isoabsorptive point), where its correlation coefficient was calculated from the standard curve which is in range of 0.993–0.996. The above-mentioned method was found to comply all the validation parameters as per the ICH guidelines such as accuracy, precision, linearity, LOD, LOQ, reproducibility and recovery. This method is successfully applied to estimate the combination of these two drugs in their pharmaceutical dosage forms without and interaction of their excipients. This method is based on to check the stability of amoxicillin trihydrate in different pH media in the presence of acetaminophen.</p><h3>Conclusion</h3><p>Hydrolysis of beta-lactam ring of amoxicillin trihydrate occurs in acidic pH (below 2) which causes the formation of amoxicilloic acid which may cause reduction in its microbial activity but neither shifting of wavelength nor appearance of extra peak occurred in UV spectroscopy. Although some changes of % area of amoxicillin trihydrate is observed in acidic media in HPLC method, there are no significant changes observed among the amoxicillin trihydrate solutions with acetaminophen prepared in different pH media, when using UV spectrophotometric method.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"10 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://fjps.springeropen.com/counter/pdf/10.1186/s43094-024-00747-6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142761745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Isolation, partial characterization, therapeutic, and safety evaluation of carbapenem-resistant Acinetobacter baumannii lytic phage in a mouse model","authors":"Hany S. Ahmed,&nbsp;Mohammed A. Eid,&nbsp;Amal M. Abo Kamer,&nbsp;Eman A. Hatem,&nbsp;Galal Yahya,&nbsp;Yehia A.-G. Mahmoud","doi":"10.1186/s43094-024-00744-9","DOIUrl":"10.1186/s43094-024-00744-9","url":null,"abstract":"<div><h3>Background</h3><p>Antimicrobial resistance (AMR) is a major worldwide health concern, characterized by the ability of microorganisms to withstand the effects of medications that once effectively treated infections. Phage therapy has emerged as a promising alternative for management of multidrug-resistant (MDR) bacterial infections. <i>Acinetobacter baumannii</i> (<i>A. baumannii</i>) exemplifies the emergence of bacteria resistant to clinically relevant antimicrobials, leading to severe nosocomial infections and exhibiting extensive and pan drug-resistant (XDR and PDR) traits. In response, this study isolated <i>A. baumannii</i> virulent phage designated as vB_AbaP_PhE54 against carbapenem-resistant <i>A. baumannii</i> (CRAB) pathogen and examined its morphological characteristics using an electron micrograph. Phage stability at different temperatures, pH, chloroform, safety, therapeutic evaluation, and growth kinetics have been analyzed.</p><h3>Results</h3><p>The <i>A. baumannii</i> phage vB_AbaP_PhE54 belongs morphologically to the <i>Podoviridae</i> family with very short, noncontractile tails, the phage demonstrated high thermal tolerance and infectivity across a pH range of 4–11, although it displayed a narrow host range. One-step growth kinetics indicated a burst size of 85 PFU (Plaque Forming Unit) per infected cell and a latent period of 20 min. Additionally, therapeutic efficiency in a mouse model showed total elimination of CRAB pathogen from lungs homogenates of mice and recovery from lung inflammation in all infected mice. On the other hand, safety evaluation of isolated phage revealed no adverse effects on structural or morphological tissue integrity.</p><h3>Conclusions</h3><p>These findings suggest that <i>A. baumannii</i> phage vB_AbaP_PhE54 could be a viable safe therapeutic option against <i>A. baumannii</i> infections, warranting further research into its clinical applications.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"10 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://fjps.springeropen.com/counter/pdf/10.1186/s43094-024-00744-9","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142761744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phytoremediation and ethnomedicinal potential of Buddleja, Eremophila, Scrophularia, and Verbascum genera belonging to the Scrophulariaceae family: a review","authors":"Alicia Monserrat Vazquez-Marquez,&nbsp;José Correa-Basurto,&nbsp;Víctor Varela-Guerrero,&nbsp;María Guadalupe González-Pedroza,&nbsp;Carmen Zepeda-Gómez,&nbsp;Cristina Burrola-Aguilar,&nbsp;Aurelio Nieto-Trujillo,&nbsp;María Elena Estrada-Zúñiga","doi":"10.1186/s43094-024-00742-x","DOIUrl":"10.1186/s43094-024-00742-x","url":null,"abstract":"<div><p>A number of species have developed detoxification strategies that allow them to accumulate high amounts of heavy metals in their tissues and grow despite a high heavy metal (HM) concentration in soils. Thus, they are considered hyperaccumulator or accumulator species, attractive for phytoremediation purposes. Families reported to contain a high number of hyperaccumulator species are Asteraceae, Euphorbiaceae, Rubiaceae, Fabaceae, Scrophulariaceae, Myrtaceae, Proteaceae, Caryophylaceae, and Tiliaceae. Indeed, the family Scrophulariaceae has a large extension, with <i>Buddleja</i>, <i>Eremophila</i>, <i>Scrophularia</i>, and <i>Verbascum</i> being some of the best-known genera containing species used for medicinal purposes. This review focuses on identifying the species used in folk medicine that belong to these four genera and can accumulate high concentrations of heavy metals (HMs). Additionally, the human health risks related to the consumption of HM hyperaccumulator species are discussed, as well as the feasibility of plant tissue culture to provide safe vegetal material for medicinal uses or to estimate the intrinsic potential of species for phytoremediation purposes. The following species have demonstrated the ability to accumulate HMs and grow in mine or HM-polluted soils, as well as use in traditional medicine: <i>Buddleja asiatica</i>, <i>B. cordata</i>, <i>B. davidii</i>, <i>B. lindleyana</i>, <i>B. macrostachya</i>, <i>B. paniculata</i>, <i>B. scordioides</i>, <i>Eremophila latrobei</i>, <i>Scrophularia canina</i> subsp. <i>bicolor</i>, <i>S. ningpoensis</i>, <i>S. striata</i>, <i>Verbascum bombyciferum</i>, <i>V. olympicum</i>, <i>V. phrygium</i>, and <i>V. thapsus.</i> In some of these species, antioxidant machinery has been proven to participate as a defense strategy against exposure to high HM concentrations. Consuming plants that accumulate high amounts of HMs has been described as a potential risk to human health. Plant tissue culture has also been established in a few of these species, whether to propagate or use them as a bioactive phytochemical source. Promoting safety and quality control related to the HM concentrations in the tissues of these plants used by populations for curative purposes is necessary. Further research must be carried out on several species for phytoremediation purposes.</p><h3>Graphical abstract</h3>\u0000<div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"10 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://fjps.springeropen.com/counter/pdf/10.1186/s43094-024-00742-x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142761906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and validation of a UV spectrophotometric method for simultaneous estimation of teneligliptin hydrobromide hydrate and pioglitazone hydrochloride in pharmaceutical dosage form","authors":"Ravi Shankar Gupta,&nbsp;Akhilesh Tiwari,&nbsp;Sanjeev Kumar Patel,&nbsp;Chandrabose Karthikeyan,&nbsp;Deepak Kumar Gupta,&nbsp;Pranay Soni,&nbsp;Megha Joshi","doi":"10.1186/s43094-024-00745-8","DOIUrl":"10.1186/s43094-024-00745-8","url":null,"abstract":"<div><h3>Background</h3><p>This study presents the development and validation of a UV spectrophotometric method for the simultaneous estimation of teneligliptin hydrobromide hydrate (TEN) and pioglitazone hydrochloride (PIO) in pharmaceutical dosage forms. The method measures absorbance at 243 nm for TEN and 265 nm for PIO. Validation was conducted according to ICH guidelines, covering specificity, linearity, range, precision, accuracy, limit of detection, limit of quantification, and robustness.</p><h3>Results</h3><p>The method exhibited linearity in the 2–25 µg/ml concentration range for both TEN and PIO, with correlation coefficients close to 1. Precision studies showed low % RSD values, indicating excellent repeatability and minimal intra- and inter-day variability. Accuracy was confirmed through recovery studies, with results within the 98–102% range. The method demonstrated sensitivity with low LOD and LOQ values. Robustness testing showed stability and consistency under varying conditions. Analysis of tablet formulations confirmed the accurate quantification of both drugs.</p><h3>Conclusion</h3><p>The developed UV spectrophotometric method offers a simple, sensitive, and cost-effective solution for the simultaneous estimation of TEN and PIO in pharmaceutical formulations. It is suitable for routine analysis and quality assessment of tablet dosage forms.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"10 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://fjps.springeropen.com/counter/pdf/10.1186/s43094-024-00745-8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142736967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-oxidative, anti-AChE and neuroprotective effect of hydro-alcoholic extract of Sansevieria cylindrica leaves and Plumeria obtusa seed pods in Wistar rats","authors":"Sunil Shewale,&nbsp;Vaishali Undale,&nbsp;Vrushali Bhalchim,&nbsp;Mohini Kuchekar,&nbsp;Bhagyashri Warude,&nbsp;Mayur Mali","doi":"10.1186/s43094-024-00740-z","DOIUrl":"10.1186/s43094-024-00740-z","url":null,"abstract":"<p>The rising incidence of neurodegenerative diseases represents a significant global health concern. The prognosis for such diseases is often unfavorable, and patients require supportive treatment to manage their condition effectively. The present study investigated the anti-oxidative, anti-acetylcholinesterase (anti-AChE) effect of hydro-alcoholic extract of <i>Sansevieria cylindrica</i> leaves and <i>Plumeria obtusa</i> seed pods in Wistar rats. Plants were authenticated followed by pharmacognostic evaluation. The antioxidant and anti-AChE activities were evaluated by scopolamine-induced oxidative stress and acetylcholine level alterations in Wistar rats. On the 0th, 7th, and 14th days during study period behavioral parameters were evaluated, including open field test, new object recognition test, and Morris water maze task. Different antioxidant enzymes were also evaluated in brain homogenate post 7 days treatment. AChE levels in rats’ brains were assessed post 14 days of treatment. Finally, histopathology of brains samples was performed. Correspondingly, <i>in-vitro</i> and <i>in-silico</i> studies were done to support the study findings.</p><p><i>Sansevieria cylindrica</i> and <i>Plumeria obtusa</i> exhibited strong antioxidant and anti-AChE activities due to secondary metabolites content. Rearing and, line crossing by rats showed substantial alteration (<i>p</i> &lt; 0.05) by combination of both plants at high dose. The escape latency found to be reduced significantly (<i>p</i> &lt; 0.05) by <i>Sansevieria cylindrica</i> individually and in combination with <i>Plumeria obtusa</i> at all doses. The lipid peroxidation level in brain was decreased significantly than standard at 1:1 combination of plants extracts. The levels of GSH, CAT and SOD were attenuated significantly by different concentration of extracts (<i>p</i> &lt; 0.05 and <i>p</i> &lt; 0.001, respectively). The reduction in AChE levels was around 34.62% and 31.10% in male and female rats, respectively in combination of both plants at high dose compared to disease control group. It was further evident in brain histopathology. All <i>in-vivo</i> results were supported by <i>in-vitro</i> free radicals scavenging effect and <i>in-silico</i> study.</p><p>The hydro-alcoholic extracts from <i>Plumeria obtusa</i> seed pods and <i>Sansevieria cylindrica</i> leaves showed a strong natural antioxidant, and acetylcholinesterase inhibitions which can aid in the treatment of neurodegerative diseases including Alzheimer.</p>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"10 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://fjps.springeropen.com/counter/pdf/10.1186/s43094-024-00740-z","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142736961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Different approaches in management of neonatal unconjugated hyperbilirubinemia: a review article","authors":"Amira A. Fouly,&nbsp;Ehab R. Bendas,&nbsp;Yasmin A. Farid,&nbsp;Sarah Sabry,&nbsp;Dina K. Abou El Fadl","doi":"10.1186/s43094-024-00741-y","DOIUrl":"10.1186/s43094-024-00741-y","url":null,"abstract":"<div><h3>Background</h3><p>Neonatal hyperbilirubinemia is a prevalent condition that affects newborns, characterized by elevated serum bilirubin levels. The accumulation of bilirubin can cause neurotoxicity, resulting in various complications, and in severe cases, even mortality. The underlying pathophysiology of this condition primarily involves an inconsistency between the synthesis and excretion of bilirubin. Despite the short- and long-term side effects of phototherapy, it is considered a core treatment of neonatal hyperbilirubinemia. Exchange transfusion is considered a last resort in cases where phototherapy fails. Several studies have investigated the use of various agents either to replace phototherapy or to be added as adjuvants to reduce the time required for phototherapy and hence minimize the adverse effects. Some of these studies have demonstrated positive outcomes, indicating their effectiveness, while others have failed to yield any significant differences in treatment duration.</p><h3>Main text</h3><p>The present review summarized the etiology of neonatal hyperbilirubinemia. It was demonstrated that neonatal hyperbilirubinemia has mainly two types: Conjugated and unconjugated hyperbilirubinemia. Treatment options for neonatal hyperbilirubinemia were discussed with phototherapy as the most prevalent and successful option followed by exchange transfusion. Side effects of phototherapy were also discussed together with the different approaches introduced to clinical practice to minimize these side effects.</p><h3>Conclusion</h3><p>Phototherapy is the most successful treatment of neonatal hyperbilirubinemia, although its side effects are of great concern. Studies introducing adjuvants such as zinc sulfate and ursodeoxycholic acid have demonstrated promising results in reducing the duration of phototherapy and minimizing the side effects. However, these results are inconclusive, and further research is required to validate the safety and efficacy of these adjuvants.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"10 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://fjps.springeropen.com/counter/pdf/10.1186/s43094-024-00741-y","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142737094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Red, green, and blue model assessment and AQbD approach to HPTLC method for concomitant analysis of metformin, pioglitazone, and teneligliptin","authors":"Pintu Prajapati,&nbsp;Pooja Patel,&nbsp;Dhrumi Naik,&nbsp;Anzarul Haque,&nbsp;Shailesh Shah","doi":"10.1186/s43094-024-00746-7","DOIUrl":"10.1186/s43094-024-00746-7","url":null,"abstract":"<div><h3>Background</h3><p>The CDSCO of India has authorized a combination of metformin hydrochloride, teneligliptin hydrochloride, and pioglitazone hydrochloride for the treatment of insulin-independent diabetes. For the purpose of estimating metformin, teneligliptin, and pioglitazone combinations as well as individual commercial formulations, there are a plethora of publicly accessible chromatographic techniques. More importantly, the development of these chromatographic procedures has included the use of chemical solvents that are dangerous to both animals and the environment.</p><h3>Objectives</h3><p>However, to date, there has been no documented chromatographic technique that can concomitantly estimate various commercial formulations of drugs under study employing a uniform chromatographic condition and environmentally friendly solvents. In order to concomitantly estimate drugs under study utilizing unified chromatographic conditions, a green HPTLC method was developed.</p><h3>Method</h3><p>The AQbD approach was used to carry out the method development. To determine the most important method parameters and response variables, the analytical risk assessment was conducted using the risk priority number ranking and screening approach. Critical method parameters and response variables were modeled using the response surface modeling approach, which relies on the central composite design. Optimal ranges for the intended method operable design region were determined, and control strategy was framed. The chromatographic separation was carried out on preparative TLC plate precoated with silica gel G-60 F₂₅₄ using 1.0%W/V ammonium acetate in ethanol: water: triethylamine (6.5:0.4:0.6, V/V) as mobile phase. The detection of the anti-diabetic drugs under study was carried out at 267 nm wavelength.</p><h3>Results</h3><p>The linearity of metformin, teneligliptin, and pioglitazone was found to be 5000–25000 ng/band, 200–1000 ng/band, and 150–750 ng/band, respectively. The %RSD for robustness and precision study was found to be less than 2.0%. The %recovery of method was found to be 98–102%. The assay results were shown to be in compliance with respective labeled claims of anti-diabetic medications when the suggested method was used for concurrent analysis of several formulations and combinations of drugs under study.</p><h3>Conclusion</h3><p>The suggested technique was evaluated utilizing red–green–blue model scoring tools. The suggested technique was determined to be precise, accurate, rapid, cost-effective, and easy to apply for the estimation of drugs under study.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"10 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://fjps.springeropen.com/counter/pdf/10.1186/s43094-024-00746-7","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142714271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of ziltivekimab in patients with chronic kidney disease susceptible to inflammatory diseases: a systematic review and meta-analysis of randomized controlled trials","authors":"Amr Elrosasy,&nbsp;Dalal Sabbagh,&nbsp;Mohammad Assaf,&nbsp;Husam Tarakhan,&nbsp;Ahmad Afyouni,&nbsp;Marwa O. Elgendy,&nbsp;Lamiaa N. Abdelaty,&nbsp;Refaat H. Omar,&nbsp;Ahmed Hamdy Zabady","doi":"10.1186/s43094-024-00723-0","DOIUrl":"10.1186/s43094-024-00723-0","url":null,"abstract":"<div><h3>Background</h3><p>Patients with chronic kidney disease (CKD) are at risk of developing conditions such as atherosclerosis and inflammation-induced anemia (AI) due to persistent inflammation. Ziltivekimab, an antibody targeting interleukin-6, is being studied for its potential to reduce inflammatory markers in these patients.</p><h3>Methods</h3><p>Following PRISMA guidelines, we searched for relevant randomized controlled trials (RCTs) up to August 20, 2023, and analyzed the data using RevMan 5.4 software. The study period spanned from February 18, 2023, to September 23, 2023. We assessed efficacy outcomes such as high-sensitivity C-reactive protein (hs-CRP), serum amyloid A (SAA), and both high-density lipoprotein (HDL) and low-density lipoprotein (LDL), as well as safety outcomes, including adverse events (AEs) and infections. Pooled results were calculated using the random effects model and inverse variance method, with mean differences (MD) and risk ratios (RR) presented alongside 95% confidence intervals (CI).</p><h3>Results</h3><p>Our review included three RCTs with a total of 473 patients. Compared to the placebo group, patients treated with ziltivekimab showed significantly lower levels of hs-CRP, fibrinogen, and SAA (MD = − 51.64, 95% CI [− 73.73 to − 29.56], <i>P</i> &lt; 0.00001; MD = − 48.23, 95% CI [− 61.73 to − 34.72], <i>P</i> &lt; 0.00001; MD = − 26.34, 95% CI [− 38.63 to − 14.04], <i>P</i> &lt; 0.0001, respectively). There was a notable increase in LDL and HDL levels (MD = 5.92, 95% CI [2.53 to 9.31], <i>P</i> = 0.0006, I² = 0%; MD = − 5.73, 95% CI [3.75 to 7.71], <i>P</i> &lt; 0.00001, I² = 0%, respectively). No significant difference in AEs or infections was observed between the two groups. Meta-regression analysis indicated a significant linear relationship between the dose of ziltivekimab and its  effect on hs-CRP levels.</p><h3>Conclusion</h3><p>Ziltivekimab showed promise in significantly lowering inflammatory markers without a significant impact on AEs or infections, positioning it as a valuable treatment option for patients with chronic kidney disease CKD who are susceptible to inflammatory diseases, particularly atherosclerosis and autoimmune conditions.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"10 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://fjps.springeropen.com/counter/pdf/10.1186/s43094-024-00723-0","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142714338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}